Article

New opening: Cash departs Alcon board for Microsoft committee

H?nenberg, Switzerland-James I. Cash Jr., PhD, has resigned from Alcon Inc.'s board of directors, citing increased demands on his time.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
Related Content
Aflibercept treat-and-extend regimen for neovascular AMD: 5-year outcomes
March 19th 2025

Aflibercept treat-and-extend regimen for neovascular AMD: 5-year outcomes

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Bausch + Lomb announces launch of new intelligent Arise lens fitting system
March 18th 2025

Bausch + Lomb announces launch of new intelligent Arise lens fitting system

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

HanAll Biopharma receives Orphan Drug Designation in Japan for Batoclimab for thyroid eye disease
March 18th 2025

HanAll Biopharma receives Orphan Drug Designation in Japan for Batoclimab for thyroid eye disease

Innovent Biologics announces approval of SYCUME in China for thyroid eye disease
March 18th 2025

Innovent Biologics announces approval of SYCUME in China for thyroid eye disease

© 2025 MJH Life Sciences

All rights reserved.